New mechanisms for PRLr action in breast cancer

Trends in Endocrinology and Metabolism

Volumn 20, Issue 5, 2009, Pages 223-229

  Clevenger, Charles V ^a   Gadd, Samantha L ^b   Zheng, Jiamao ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; CYCLOSPORIN A; ERYTHROPOIETIN RECEPTOR; ESTROGEN RECEPTOR; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; PEPTIDYLPROLYL ISOMERASE; PROLACTIN; PROLACTIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG TARGETING; ENZYME ACTIVATION; HORMONE ACTION; HUMAN; ISOMERIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CYCLOPHILIN A; FEMALE; HUMANS; MODELS, BIOLOGICAL; PROLACTIN; PROTEIN MULTIMERIZATION; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION;

EID: 67649216555     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.03.001     Document Type: Review

References (58)

1. Bachelot A., and Binart N. Reproductive role of prolactin. Reproduction 133 (2007) 361-369
2. Clevenger C.V., et al. The role of prolactin in mammary carcinoma. Endocr. Rev. 24 (2003) 1-27
3. Harris J., et al. Prolactin and the prolactin receptor: new targets of an old hormone. Ann. Med. 36 (2004) 414-425
4. Perks C.M., et al. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer 91 (2004) 305-311
5. Maus M.V., et al. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140 (1999) 5447-5450
6. Ormandy C.J., et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 11 (1997) 167-178
7. Horseman N.D., et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 16 (1997) 6926-6935
8. Graichen R., et al. The growth hormone-binding protein is a location-dependent cytokine receptor transcriptional enhancer. J. Biol. Chem. 278 (2003) 6346-6354
9. Hankinson S.E., et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 91 (1999) 629-634
10. Wennbo H., et al. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Invest. 100 (1997) 2744-2751
11. Clevenger C.V. Role of Stat family transcription factors in human breast cancer. Am. J. Pathol. 165 (2004) 1449-1460
12. Miller S.L., et al. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol. Endocrinol. 19 (2004) 939-949
13. Miller S.L., et al. Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 26 (2007) 4668-4678
14. Brockman J.L., et al. PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol. Endocrinol. 16 (2002) 774-784
15. Fang F., et al. Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol. 8 (2008) 1-11
16. Sakamoto K., et al. The Janus kinase 2 (Jak2) is required for expression and nuclear accumulation of Cyclin D1 in proliferating mammary epithelial cells. Mol. Endocrinol. 21 (2007) 2218-2232
17. Wagner K.-U., et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol. Cell. Biol. 24 (2004) 5510-5520
18. Pezet A., et al. The last proline of box 1 is essential for association with JAK2 and functional activation of the prolactin receptor. Mol. Cell. Endocrinol. 129 (1997) 199-208
19. Pezet A., et al. Tyrosine docking sites of the rat prolactin receptor required for association and activation Stat5. J. Biol. Chem. 272 (1997) 25043-25050
20. He K., et al. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol. Endocrinol. 17 (2003) 2211-2227
21. Xie J., et al. Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. J. Biol. Chem. 277 (2002) 14020-14030
22. Yamauchi T., et al. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J. Biol. Chem. 275 (2000) 33937-33944
23. Waters M.J., et al. New insights into growth hormone action. J. Mol. Endocrinol. 36 (2006) 1-7
24. Harding P., et al. Growth hormone and a GH antogonist promote GH receptor dimerization and internalization. Bioessays 271 (1996) 6708-6712
25. Ross R.J.M., et al. Binding and functional studies with the growth hormone receptor antagonist B2036-PEG (Pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J. Clin. Endocrinol. Metab. 86 (2001) 1716-1723
26. Gent J., et al. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9858-9863
27. Yang N., et al. Role of growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol. Endocrinol. 21 (2007) 1642-1655
28. Brown R.J., et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12 (2005) 814-821
29. Mellado M., et al. Conformational changes required in the human growth hormone receptor for growth hormone signaling. J. Biol. Chem. 272 (1997) 9189-9196
30. Constantinescu S.N., et al. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol. Cell 7 (2001) 377-385
31. Seubert N., et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol. Cell 12 (2003) 1239-1250
32. Gertler A., et al. Real-time measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model hormone-induced transient receptor dimerization. J. Biol. Chem. 271 (1996) 24482-24491
33. Biener E., et al. Ovine placental lactogen-induced heterodimerization of ovine growth hormone and prolactin receptors in living cells is demonstrated by fluorescence resonance energy transfer microscopy and leads to prolonged phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT3. Endocrinology 144 (2003) 3532-3540
34. Tan D., et al. Unmodified prolactin (PRL) and S179D Prl-initiated bioluminescence resonance energy transfer between homo - and hetero - pairs of long and short human PRL receptors in living human cells. Mol. Endocrinol. 19 (2005) 1291-1303
35. Qazi A.M., et al. Ligand-independent homo- and hetero-dimerization of human prolactin receptor variants: inhibitory action of the short forms by hetrodimerization. Mol. Endocrinol. 26 (2006) 6748-6761
36. Gadd S., and Clevenger C.V. Ligand-independent dimerization of the human prolactin receptor: functional implications. Mol. Endocrinol. 20 (2006) 2734-2746
37. Colgan J., et al. Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J. Immunol. 174 (2005) 6030-6038
38. Edlich F., and Fischer G. Pharmacologic targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases. Handbook of Experimental Pharmacology 172 (2006) 359-404
39. Wang P., and Heitman J. The cyclophilins. Genome Biol. 6 (2005) 226
40. Lu K.P., et al. Prolyl cis-trans isomerization as a molecular timer. Nat. Chem. Biol. 3 (2007) 619-629
41. Chen Y.-G., et al. Mechanisms of TGFβ receptor inhibition by FKB12. EMBO J. 16 (1997) 3866-3876
42. Lopez-Ilasaca M., et al. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J. Biol. Chem. 273 (1998) 9430-9434
43. Brazin K.N., et al. Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1899-1904
44. Leverson J.D., and Ness S.A. Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. Mol. Cell 1 (1998) 203-211
45. Mamane Y., et al. Postranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity 12 (2000) 129-140
46. Rycyzyn M.A., et al. Role of cyclophilin B in PRL signal transduction and nuclear retrotranslocation. Mol. Endocrinol. 14 (2000) 1175-1186
47. Rycyzyn M.A., and Clevenger C.V. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6790-6795
48. Fang F., et al. Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am. J. Pathol. 174 (2009) 297-308
49. Syed F., et al. A novel and functional interaction between cyclophilin (Cyp) A and the prolactin receptor. Endocrine 20 (2003) 83-89
50. Zheng J., et al. Peptidyl-prolyl isomerase regulation of Jak2 activation and the progression of human breast cancer. Cancer Res. 68 (2008) 7769-7778
51. Stewart T., et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346 (1995) 796-798
52. Kline J.B., and Clevenger C.V. Identification and characterization of the prolactin-binding protein (PRLBP) in human serum and milk. J. Biol. Chem. 276 (2001) 24760-24766
53. Yao Q., et al. Roles of cyclophilins in cancers and other organ systems. World J. Surg. 29 (2005) 276-280
54. Howard B.A., et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 65 (2005) 8853-8860
55. Shen J., et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64 (2004) 9018-9026
56. Rey O., et al. Differential gene expression in neoplastic and human papillomavirus-immortalized oral keratinocytes. Oncogene 18 (1999) 827-831
57. Campa M.J., et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 63 (2003) 1652-1656
58. Choi K.J., et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res. 67 (2007) 3654-3662